SPONTAN Phase II Clinical Study Completes Recruitment
Filed with ASX · · 2 pages · English
Summary by 6ix AI
LTR Pharma Limited has announced the completion of recruitment for its SPONTAN Phase II pharmacokinetic clinical study, with all participants enrolled across three cohorts. The final cohort is currently undergoing dosing at a clinical research facility, with a focus on a dedicated group of older participants. This study is designed in accordance with FDA guidance, and initial data is expected in the second quarter of the following year. The Executive Chairman emphasized that this milestone demonstrates the company's disciplined execution of its clinical program.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from LTR Pharma
- Appendix 4D and Half Yearly Report
- SPONTAN Shows Positive Outcomes in Younger Men with ED
- Quarterly Activities/Appendix 4C Cash Flow Report
- First Patients Dosed in SPONTAN Phase II Clinical Study
- TGA Provides Regulatory Clearance for SPONTAN Phase II
Later from LTR Pharma
- SPONTAN Phase II data show rapid onset, support FDA pathway
- SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations
- LTR Secures First U.S. Commercial Agreement for ROXUS
- LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS
- Response to ASX Aware Letter
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma